Cura Technologies Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 18, 2026
- Posted by: Kunal Singla
- Category: News
The Cura Technologies share price target 2026 is Rs 105, implying approximately 20 percent upside from the current market price of Rs 86.6 (NSE: CURAA). With Q4 FY26 results released in 2026 and Pharmaceutical Specialty Products tailwinds in focus, the Rs 105 price objective is supported by the FY27 earnings recovery thesis.
Cura Technologies (NSE: CURAA) is a Pharmaceutical Specialty Products company trading at Rs 86.6 with a market capitalisation of Rs 433 crore. Analysts have set the Cura Technologies share price target at Rs 105 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Cura Technologies Share Price Target 2026: Key Takeaways
- Cura Technologies share price target 2026: Rs 105 (20% upside from CMP Rs 86.6)
- Bull case: Rs 125 | Bear case: Rs 69.3
- Ticker: CURAA | Sector: Pharmaceutical Specialty Products | MCap: Rs 433 crore
- 52W range: Rs 60 to Rs 151 | PE: 20x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Cura Technologies Company Overview
Cura Technologies (NSE: CURAA) is a pharmaceutical specialty products company listed in 2025, providing specialty drug formulations and healthcare products to domestic hospitals and clinics across therapeutic areas. At CMP Rs 86.6 against a 52 week range of Rs 60 to Rs 151, the stock trades at a discount to its 52 week high. Market capitalisation is Rs 433 crore with trailing PE of 20x. Compared to peers in specialty pharma like Gufic Biosciences and Anuh Pharma, Cura Technologies is positioned as a potential re-rating candidate toward the Rs 105 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | CURAA |
| Sector | Pharmaceutical Specialty Products |
| CMP (2026) | Rs 86.6 |
| 52 Week High | Rs 151 |
| 52 Week Low | Rs 60 |
| Market Cap | Rs 433 crore |
| Trailing PE | 20x |
| 12-Month Analyst Target | Rs 105 |
| Bull Case Target | Rs 125 |
| Bear Case Target | Rs 69.3 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Why Is the Cura Technologies Share Price Target Set at Rs 105 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Cura Technologies share price target of Rs 105 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating from CMP Rs 86.6. The Rs 105 price objective represents the base case with FY27 execution as the key variable.
Structural Sector Tailwinds in Pharmaceutical Specialty Products
The Pharmaceutical Specialty Products sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Cura Technologies’s market position among peers in specialty pharma like Gufic Biosciences and Anuh Pharma creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 125 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Cura Technologies’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 105 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable policy backdrop for Cura Technologies’s Pharmaceutical Specialty Products operations, improving the probability of achieving the FY27 earnings targets that support the Rs 105 price objective.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 20x PE, Cura Technologies is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 125 bull case over the medium term.
Cura Technologies Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Cura Technologies Share Price Target
Near-term support for Cura Technologies is anchored close to the 52 week low of Rs 60. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.
12-Month Cura Technologies Share Price Target 2026
The 12-month Cura Technologies share price target 2026 is Rs 105, implying approximately 20 percent upside from CMP Rs 86.6. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker CURAA.
Long Term Cura Technologies Share Price Target: FY27 to FY28
The long term Cura Technologies share price target for FY27 to FY28 is Rs 125 in the bull case, requiring full earnings delivery, re-rating among peers in specialty pharma like Gufic Biosciences and Anuh Pharma, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Cura Technologies in 2026
Bull Case Cura Technologies Share Price Target: Rs 125
The bull case Cura Technologies share price target of Rs 125 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Specialty Products tailwinds accelerate, and FII flows return strongly to Indian equities, enabling re-rating toward higher peer multiples. From CMP Rs 86.6, this represents approximately 45 percent potential upside.
Bear Case Cura Technologies Share Price Target: Rs 69.3
The bear case Cura Technologies share price target of Rs 69.3 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of the 52 week low support near Rs 60.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 125 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 105 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 69.3 | FY27 miss, guidance cut, FII outflows |
Key Risks That Could Derail the Cura Technologies 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Cura Technologies share price target of Rs 105, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 105 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Pharmaceutical Specialty Products Peers
Intensifying competition from peers in specialty pharma like Gufic Biosciences and Anuh Pharma could compress Cura Technologies’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory that underpins the Rs 105 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should size positions carefully and maintain stop losses to protect capital if broad market de-rating continues.
How to Invest in Cura Technologies
Check the Univest Screener for live data
Before considering any investment based on the Cura Technologies share price target of Rs 105, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Specialty Products sector demand and competition.
Open a Demat account with a SEBI registered stockbroker to trade Cura Technologies (NSE: CURAA) with regulatory protection. Study the competitive landscape among peers in specialty pharma like Gufic Biosciences and Anuh Pharma before executing any position.
Plan your entry using the 52 week low of Rs 60 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 105 price target. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio, especially in the Pharmaceutical Specialty Products space where sectoral cycles can amplify volatility beyond initial expectations.
Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Cura Technologies’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Cura Technologies Share Price Target 2026
What is the Cura Technologies share price target for 2026?
Ans. The Cura Technologies share price target 2026 is Rs 105, implying approximately 20 percent upside from CMP Rs 86.6. Bull case is Rs 125, bear case is Rs 69.3.
What was the Cura Technologies share price target for 2025?
Ans. The 2025 price objective for Cura Technologies was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 105, reflecting FY27 growth potential from CMP Rs 86.6.
Is Cura Technologies a good investment at Rs 86.6?
Ans. At Rs 86.6, Cura Technologies offers potential upside toward Rs 105 if FY27 earnings recover. Consult a SEBI registered financial advisor before investing based on any price target.
What are the key risks to the Cura Technologies share price target 2026?
Ans. Key risks to the Cura Technologies share price target of Rs 105 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Specialty Products. Monitoring quarterly results is essential.
What is the 52 week high and low of Cura Technologies?
Ans. The 52 week high of Cura Technologies is Rs 151 and the 52 week low is Rs 60. At CMP Rs 86.6, the stock is below its 52 week high and offers upside toward the Rs 105 price objective.
What are the main growth catalysts for Cura Technologies in 2026?
Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Specialty Products tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Cura Technologies compare to its peers?
Ans. Cura Technologies operates in Pharmaceutical Specialty Products alongside peers in specialty pharma like Gufic Biosciences and Anuh Pharma. At CMP Rs 86.6 with MCap Rs 433 crore, it is a potential re-rating candidate toward the Cura Technologies share price target of Rs 105 on FY27 delivery.
What is the Cura Technologies share price target for 2027?
Ans. The long-term Cura Technologies share price target for FY27 to FY28 is Rs 125 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
